Peer-influenced content. Sources you trust. No registration required. This is HCN.
Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial.
Family Medicine/General Practice May 4th 2020
Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.
Allergy & Immunology April 27th 2020
JAMA Network
A comprehensive guide from the American Medical Association (AMA), which includes information for those who want to support communities severely impacted by COVID-19, including the how and where to volunteer and all things to consider.
Allergy & Immunology April 13th 2020
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH